OncoMatch/Clinical Trials/NCT05007132
Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Is NCT05007132 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Panitumumab 20 milligram/ML and Bevacizumab for metastatic colorectal cancer.
Treatment: Panitumumab 20 milligram/ML · Bevacizumab · Trifluridine/Tipiracil Hydrochloride — FIRE-8 is a prospective, randomized, open label, multicenter phase II clinical trial. To evaluate the effecacy of trifluridine / tipiracil and panitumumab (Arm A) compared to trifluridine / tipiracil and bevacizumab (Arm B), participants will be randomly assigned to either Arm A or Arm B for the treatment of metastatic colorectal cancer. The primary objectives of this study is to compare the effecacy of treatment with trifluridine / tipiracil plus panitumumab versus trifluridine / tipiracil plus bevacizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS wild-type
Required: NRAS wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Metastatic colorectal cancer (mCRC) with at least one measurable lesion according to RECIST 1.1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy for metastatic disease
Exception: Prior adjuvant chemotherapy is permitted, if completed > 3 months prior to randomisation. Multimodal treatment of rectal cancer is not considered antimetastatic therapy and does not preclude study participation.
Prior systemic therapy of metastatic disease. Note: Prior adjuvant chemotherapy is permitted, if completed > 3 months prior to randomisation. Multimodal treatment of rectal cancer is not considered antimetastatic therapy and does not preclude study participation
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/L (1500/μL); Hemoglobin ≥ 80 g/L (8 g/dL); Platelet count ≥ 75 x10^9/L (75,000/μL) without transfusion
Kidney function
Calculated GFR ≥ 30 mL/min or serum creatinine ≤ 1.5 x ULN
Liver function
Total serum bilirubin of ≤ 1.5 x ULN; AST/GOT and ALT/GPT ≤ 2.5 × ULN; if liver function abnormalities are due to underlying liver metastasis, AST and ALT ≤ 5 × ULN
Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results: ... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify